EP Patent

EP3153170B1 — Methods and uses of the quinoline derivative anlotinib in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same

Assigned to Advenchen Laboratories Nanjing Ltd · Expires 2025-08-13 · 1y expired

What this patent protects

Patent listed against umbralisib-tosylate.

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: EP3153170B1
Jurisdiction: EP
Classification: —
Expires: 2025-08-13
Drug substance claim: No
Drug product claim: No
Assignee: Advenchen Laboratories Nanjing Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.